These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 1657508

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L, Dundarov S, Andonov P, Bakalov B, Dundarova D, Brodvarova I.
    Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
    [Abstract] [Full Text] [Related]

  • 31. Papillomavirus-like particles and HPV vaccine development.
    Schiller JT, Lowy DR.
    Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
    Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L.
    Ann Intern Med; 1995 Jun 15; 122(12):889-98. PubMed ID: 7755223
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF, Makhmudov FR.
    Vopr Virusol; 2010 Jun 15; 55(1):35-40. PubMed ID: 20364670
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.
    Skinner GR, Williams DR, Buchan A, Whitney J, Harding M, Bodfish K.
    Med Microbiol Immunol; 1978 Nov 17; 166(1-4):119-32. PubMed ID: 214676
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.